AEOL 10150

Drug Profile

AEOL 10150

Alternative Names: AEOL-10150; MnTDEIP

Latest Information Update: 11 Apr 2017

Price : $50

At a glance

  • Originator Duke University; National Jewish Medical and Research Center
  • Developer Aeolus Pharmaceuticals Inc; National Institutes of Health (USA); National Jewish Medical and Research Center; United States Army Medical Research Institute of Chemical Defense; University of Colorado at Denver
  • Class Oxidoreductases; Porphyrins; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Antioxidants; Free radical scavengers; Oxygen radical scavengers; Reactive oxygen species inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Acute radiation syndrome; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Idiopathic pulmonary fibrosis; Solid tumours
  • Suspended Amyotrophic lateral sclerosis
  • Discontinued Acute lung injury; Acute radiation syndrome; Chronic obstructive pulmonary disease; Cystic fibrosis; Diabetes mellitus; Gastrointestinal disorders; Lung disorders; Mucositis; Poisoning; Radiation injuries; Skin disorders; Spinal cord injuries; Stroke

Most Recent Events

  • 23 Mar 2017 Pharmacodynamics data from preclinical trials in Pulmonary acute radiation syndrome released by Aeolus Pharmaceuticals
  • 23 Mar 2017 Discontinued - Phase-I for Acute radiation syndrome (In volunteers) in USA (SC)
  • 23 Mar 2017 Discontinued - Preclinical for Acute lung injury in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top